Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -127.00K | -222.00K | -260.00K | -285.00K | EBIT |
-26.64M | -29.63M | -30.64M | -22.97M | -19.74M | EBITDA |
-26.52M | -29.50M | -30.51M | -22.80M | -19.54M | Net Income Common Stockholders |
-21.76M | -29.77M | -27.41M | -8.86M | -15.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
4.28M | 23.55M | 43.15M | 70.90M | 15.17M | Total Assets |
16.93M | 38.22M | 57.42M | 84.09M | 29.03M | Total Debt |
478.00K | 574.00K | 451.00K | 159.00K | 277.00K | Net Debt |
-3.80M | -22.98M | -42.69M | -70.74M | -14.90M | Total Liabilities |
10.95M | 12.14M | 5.23M | 5.10M | 11.27M | Stockholders Equity |
5.98M | 26.07M | 52.19M | 78.99M | 17.76M |
Cash Flow | Free Cash Flow | |||
-23.88M | -24.23M | -27.71M | -18.97M | -18.15M | Operating Cash Flow |
-23.86M | -24.10M | -27.64M | -18.95M | -17.77M | Investing Cash Flow |
-13.00K | -124.00K | -67.00K | -19.00K | -374.00K | Financing Cash Flow |
4.63M | 4.65M | -23.00K | 74.72M | 22.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $248.02M | ― | -33.88% | ― | ― | -22.66% | |
42 Neutral | $9.64M | ― | -52.85% | ― | ― | 8.99% | |
36 Underperform | $47.69M | ― | -807.39% | ― | -80.98% | 62.27% | |
36 Underperform | $96.01M | ― | -424.44% | ― | ― | 51.02% | |
32 Underperform | $12.27M | ― | -135.80% | ― | ― | 52.82% |
On April 1, 2025, Moleculin Biotech announced the commencement of dosing for the first patient in its Phase 3 MIRACLE trial, which evaluates Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia (R/R AML). This trial marks a significant milestone for the company and the AML community, with initial data expected in the second half of 2025. The trial’s adaptive design and global scope aim to accelerate Annamycin’s development towards approval, potentially impacting Moleculin’s market positioning and providing valuable insights for stakeholders.
On March 24, 2025, Moleculin Biotech, Inc. utilized a corporate presentation for its website, which was detailed in a Current Report on Form 8-K. The presentation, noted as Exhibit 99.1, was shared for informational purposes and not intended for filing under the Securities Exchange Act of 1934 or the Securities Act of 1933.
On February 13, 2025, Moleculin Biotech announced receiving FDA feedback that allows a reduced size for its Phase 3 trial protocol evaluating Annamycin combined with Cytarabine for treating relapsed or refractory AML. This trial, named MIRACLE, will be conducted globally, including in the US, Europe, and the Middle East, and aims to accelerate the approval timeline for this potentially groundbreaking non-cardiotoxic anthracycline. The feedback enables quicker site openings and recruitment, with implications for significantly impacting AML treatment and eliminating cardiotoxic risks in cancer therapies.
On February 11, 2025, Moleculin Biotech announced receiving regulatory approval in Europe to start recruiting for its Phase 3 MIRACLE trial, evaluating Annamycin combined with Cytarabine for treating relapsed or refractory acute myeloid leukemia. The trial will include sites in the US, Europe, and the Middle East. The announcement signifies a crucial step in advancing their pivotal clinical trial, aiming for unblinded preliminary data from the first 45 subjects in the second half of 2025, potentially enhancing their market position in cancer therapeutics.
On January 27, 2025, Moleculin Biotech announced the launch of its MIRACLE pivotal study for second line relapsed/refractory acute myeloid leukemia (AML), marking a significant milestone in its drug development efforts. The company has made substantial progress in preparing for this global registration trial, including selecting over 25 clinical sites and expecting to activate over 70, with the first patient anticipated to be treated within the first quarter. The trial aims to complete the 90-patient Part A by early 2026. Moleculin’s drug Annamycin shows promising preliminary results, outpacing competitors, and is generating increased interest from potential partners, reflecting its potential impact on the AML treatment landscape.
On January 27, 2025, Moleculin Biotech announced that its CEO, Walter Klemp, participated in a Virtual Investor ‘What This Means’ segment. During the event, Klemp shared updates on the MIRACLE trial, a Phase 3 study evaluating Annamycin for treating relapsed or refractory acute myeloid leukemia. This trial is a significant step for Moleculin as it expands globally, with sites in the US, Europe, and the Middle East, and reflects advancements in AML treatment. Moleculin’s progress in developing Annamycin and other drug candidates could enhance its position in the pharmaceutical industry, with potential implications for regulatory approval and stakeholder investment.
Moleculin Biotech, Inc. announced the use of a corporate presentation as part of its communication strategy, which is now available on their website. This presentation is being shared for informational purposes and will not be filed under the Securities Exchange Act, which may impact how stakeholders and investors perceive the company’s communications.
Moleculin Biotech announced significant progress in the development of its drug Annamycin, particularly for relapsed or refractory acute myeloid leukemia (AML). The company has received approval for a pivotal Phase 3 trial, with initial data indicating Annamycin’s potential superiority over existing therapies. The accelerated trial timelines and promising preliminary results could enhance Moleculin’s market position and provide substantial value to stakeholders.